Voltage-dependent, open channel blockade of the cardiac sarcoplasmic reticulum potassium channel by 4-aminopyridine. 1998

Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
Department of Pharmacology, Medicine and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina, USA. chiliu@med.unc.edu

The nature of open state block was characterized in isolated canine cardiac sarcoplasmic reticulum (SR) potassium channel incorporated into planar lipid bilayers. 4-Aminopyridine (4-AP) blocked the open conductance state of the potassium channels in a voltage-dependent manner. Blockade was reversible, occurred from either the cis (cytoplasmic) or the trans (lumenal) side and was competitive with potassium ions. Reversal potential measurements indicated that this channel was impermeable to 4-AP. Measured effective electrical distances were roughly symmetrical and indicated penetration of 0.39 and 0.42 of the membrane electrical field from the cis and trans sides, respectively. Effective electrical distance was insensitive to potassium ion concentration in the range 50 to 200 mM and indicated that 4-AP was able to penetrate relatively deeply into the pore compared with blockade of sarcolemmal potassium channels. Potassium ion concentration and voltage dependence of 4-AP blockade were consistent with a two binding site blockade model, similar to the model used previously to describe calcium ion blockade of the SR potassium ion channel. Unlike calcium blockade, however, 4-AP blocked from either cis or trans in a similar manner, suggesting a distinct binding site for each of these two blockers. Open channel, voltage-dependent blockade of the SR potassium channel by 4-AP is in marked contrast to its action on sarcolemmal potassium channels and suggests that either 4-AP penetrates much farther into the potassium channel permeation pathway than was previously believed, or the SR potassium channel has a very different physical pore arrangement from that of sarcolemmal potassium channels.

UI MeSH Term Description Entries
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012519 Sarcoplasmic Reticulum A network of tubules and sacs in the cytoplasm of SKELETAL MUSCLE FIBERS that assist with muscle contraction and relaxation by releasing and storing calcium ions. Reticulum, Sarcoplasmic,Reticulums, Sarcoplasmic,Sarcoplasmic Reticulums
D015221 Potassium Channels Cell membrane glycoproteins that are selectively permeable to potassium ions. At least eight major groups of K channels exist and they are made up of dozens of different subunits. Ion Channels, Potassium,Ion Channel, Potassium,Potassium Channel,Potassium Ion Channels,Channel, Potassium,Channel, Potassium Ion,Channels, Potassium,Channels, Potassium Ion,Potassium Ion Channel
D015761 4-Aminopyridine One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes. 4-Aminopyridine Sustained Release,Dalfampridine,Fampridine-SR,Pymadine,VMI-103,4 Aminopyridine,4 Aminopyridine Sustained Release,Fampridine SR,Sustained Release, 4-Aminopyridine,VMI 103,VMI103

Related Publications

Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
March 1986, The American journal of physiology,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
January 1989, Biophysical journal,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
November 1994, The Journal of general physiology,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
January 2000, Receptors & channels,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
January 1990, The American journal of physiology,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
February 1991, Pflugers Archiv : European journal of physiology,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
May 1998, European journal of biochemistry,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
July 1991, Biophysical journal,
Q Y Liu, and R L Rasmusson, and Q X Liu, and H C Strauss
December 1977, The Journal of physiology,
Copied contents to your clipboard!